Cosmos Health To Receive Regulatory Approval For C-Scrub Disinfectant In The UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU; No Financial Terms Of Purchase Order Disclosed
Cosmos Health To Receive Regulatory Approval For C-Scrub Disinfectant In The UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU; No Financial Terms Of Purchase Order Disclosed
Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today it is in the final stages of securing regulatory approval to sell its biocide disinfectant hand soap, C-Scrub Wash 4% CHG ("C-Scrub"), in the United Kingdom (UK), and has obtained its inaugural purchase order.
Cosmos Health Inc.（“Cosmos Health” 或 “公司”）（納斯達克股票代碼：COSM）是一家從事創新研發的多元化、垂直整合的全球醫療保健集團、專有藥品和營養品品牌的所有者、醫療產品的製造商和分銷商以及遠程醫療平台的運營商。該公司今天宣佈，出售其殺菌劑消毒洗手液C-Scrub Wash 4% CHG（“C-Scrub”），位於英國（UK），並已獲得首份採購訂單。
Cosmos Health expects to obtain all necessary registration approvals from the UK's Health Security Agency (HSA), an executive agency of the Department of Health and Social Care. Approval will allow the authorized distribution of C-Scrub across the entire UK market.
Cosmos Health希望獲得英國健康保障局（HSA）的所有必要註冊批准，該局是衛生和社會保健部的執行機構。批准將允許在整個英國市場授權分銷C-Scrub。
Additionally, the Company expects to enter into agreements to supply the National Health Service (NHS), the publicly funded healthcare system of the UK, comprising the National Health Service in England, Scotland, and Wales, and the Health and Social Care in Northern Ireland.
此外，該公司預計將簽訂協議，提供國家醫療服務（NHS），這是英國公共資助的醫療體系，包括英格蘭、蘇格蘭和威爾士的國家衛生服務以及北愛爾蘭的健康和社會保健。
C-Scrub, formulated with 4% chlorhexidine gluconate and supported by extensive clinical experience, is ideal for routine hand disinfection and targets a wide range of microbes, including bacteria, viruses, and fungi. It provides immediate and prolonged antimicrobial action, effective for 6 hours, even in the presence of biological fluids. Particularly suitable for users sensitive to iodine, it does not promote resistance, includes emollients for skin health, and is cosmetically friendly. Produced at the facilities of Cana Laboratories, it is available in sizes ranging from 250ml to 20L, suitable for use in a variety of healthcare environments, including hospitals and outpatient settings such as clinics, surgery rooms, emergency departments, wards, intensive care units, surgery centers, and other medical facilities.
C-Scrub 由 4% 的葡萄糖酸氯己定配製而成，並有豐富的臨床經驗支持，是常規手部消毒的理想選擇，可靶向各種微生物，包括細菌、病毒和真菌。它提供即時和長期的抗菌作用，即使在存在生物液體的情況下也能有效6小時。特別適合對碘敏感的用戶，它不會增強抵抗力，含有促進皮膚健康的潤膚劑，對美容無害。它由 Cana Laboratories 的設施生產，尺寸從 250 毫升到 20 升不等，適用於各種醫療環境，包括醫院和門診環境，如診所、手術室、急診室、病房、重症監護室、手術中心和其他醫療設施。
According to Future Market Insights, the global hospital disinfectant products and services market size is estimated to be valued at $36.1 billion in 2023 and is expected to reach $75.6 billion by 2033. This reflects a compound annual growth rate (CAGR) of 7.7% during the forecast period, with the UK market playing a significant role.
根據未來市場洞察，到2023年，全球醫院消毒劑產品和服務的市場規模估計爲361億美元，預計到2033年將達到756億美元。這反映了預測期內複合年增長率（CAGR）爲7.7％，英國市場起着重要作用。
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "We look forward to expanding C-Scrub in the United Kingdom, a very lucrative market for us. We also look forward to entering into a collaboration with the NHS, which is expected to provide an attractive stream of cash flows for Cosmos. Moreover, we are planning to enter several key non-EU markets, eyeing the lucrative global hospital disinfectant market which is expected to surpass $75 billion by 2033."
Cosmos Health首席執行官格雷格·西奧卡斯表示：“我們期待在英國擴展C-Scrub，這對我們來說是一個非常有利可圖的市場。我們還期待與NHS進行合作，預計NHS將爲Cosmos提供有吸引力的現金流。此外，我們計劃進入幾個關鍵的非歐盟市場，着眼於利潤豐厚的全球醫院消毒劑市場，預計到2033年將超過750億美元。”
譯文內容由第三人軟體翻譯。